Presidential Initiative

Prescription Drug Importation – Protecting the US Drug Supply Chain

Caroline D. Juran, BSPharm, DPh (Hon)

Following the final rule approved by Trump Administration and published by Food and Drug Administration in 2020, states can now submit proposals to establish their own wholesale prescription drug importation program from Canada. While NABP understands the desire to decrease the costs of prescription drugs, states may face challenges while ensuring patient safety and securing the global supply chain. Increasing efforts to support the boards of pharmacy and to educate and protect the public about state drug importation plans is a key focus and the presidential initiative of NABP President Juran.

There are three areas of focus for the initiative: 

  • providing guidance to state and federal governments and other policy makers on the risks associated with prescription drug importation and the necessary regulatory oversight process to help mitigate those risks; 
  • working with state and federal regulators to implement the Drug Supply Chain Security Act (DSCSA), including providing education and other tools to regulators and supply chain participants to assist in implementation; and 
  • educating the public about the risks associated with purchasing prescription drugs from unknown sources online and through social media.  

Task Force Updates

The task force was held, and the report is posted in the Resources section.

Learn More

Increasing awareness about state importation programs is necessary to maintain patient safety. More information about prescription drug importation can be found in the below resources. 

Background Information and Guidance



Looking for more information?

Submit your email address to receive updates about the Presidential Initiative.

Presidential Initiative Interest Form

Looking for NABP Chairperson Tim Fensky’s 2020-2021 initiative? Visit the Medication-Assisted Treatment page.